Granted Patent
B2
US 12,459,982 · App. 15/533,910 · Granted Nov 4, 2025
Methods of producing long acting CTP-modified growth hormone polypeptides
Assignee:
OPKO BIOLOGISTICS LTD.
C07K14/59C07K14/505C07K14/555C07K14/575C07K14/61C12N9/6437C12N9/644C12N15/85G06Q10/0633G06Q10/0637G06Q10/06393G06Q30/0201A61K38/00C07K2319/00C07K2319/31C12M21/00C12Y304/21021C12Y304/21022
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein is a method for manufacturing a recombinant human growth hormone (h GH) modified by a CTP extension in a mammalian cells culture system.
Claims (57)
1 . A purified pharmaceutical composition comprising a highly glycosylated polypeptide and a pharmaceutically acceptable carrier, the polypeptide comprising an amino terminal chorionic gonadotropin carboxy terminal peptide (CTP), a human growth hormone (hGH) polypeptide, and two carboxy terminal chorionic gonadotropin CTPs arranged in tandem (CTP-modified hGH polypeptide), wherein the CTP-modified hGH polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 7, wherein at least 60% of the CTP-modified hGH polypeptides present in the purified pharmaceutical composition are highly glycosylated and comprise 13 to 18 O-linked glycans per molecule, and wherein the purified pharmaceutical composition is manufactured by a method comprising the steps of:
(a) stably transfecting a predetermined number of cells with an expression vector comprising a coding portion encoding the CTP-modified hGH polypeptide, wherein the transfected cells express and secrete the CTP-modified hGH polypeptide;
(b) obtaining cell clones that overexpress the CTP-modified hGH polypeptide;
(c) expanding the clones in solution to a predetermined scale by culturing at a dissolved oxygen (DO) content of 20-30%, wherein the pH of the solution is shifted from 7.2 to 6.9 during the expansion;
(d) harvesting the solution containing the clones;
(e) filtering the solution containing the clones to obtain a clarified harvest solution; and
(f) purifying the clarified harvest solution to obtain a desired concentration of the CTP-modified hGH polypeptide.
2 . The purified pharmaceutical composition according to claim 1 , wherein the O-linked glycans are located on the CTPs of the CTP-modified hGH polypeptides.
3 . The purified pharmaceutical composition according to claim 1 , wherein the CTP-modified hGH polypeptides present in the purified pharmaceutical composition that are highly glycosylated comprise at least 15 O-linked glycans per molecule.
4 . The purified pharmaceutical composition according to claim 1 , wherein two of the CTPs of the CTP-modified hGH polypeptides present in the purified pharmaceutical composition that are highly glycosylated each comprises 4, 5, or 6 O-linked glycans per molecule, and wherein one of the CTPs of the CTP-modified hGH polypeptides present in the purified pharmaceutical composition that are highly glycosylated comprises 5 or 6 O-linked glycans per molecule.
5 . The purified pharmaceutical composition according to claim 1 , wherein each of the CTP-modified hGH polypeptides comprises O-linked glycans at least at residues 10, 13, 15, 21, 229, 232, 234, 240, 257, 260, 262, and 268 of SEQ ID NO: 7.
6 . The purified pharmaceutical composition according to claim 5 , wherein the CTP-modified hGH polypeptides present in the purified pharmaceutical composition that are highly glycosylated further comprise O-linked glycans at least at two residues selected from amino acid residues 1 to 4 of SEQ ID NO: 7, at least at two residues selected from amino acid residues 220 to 223 of SEQ ID NO: 7, at least at two residues selected from amino acid residues of 248 to 251 of SEQ ID NO: 7, or any combination thereof.
7 . The purified pharmaceutical composition according to claim 1 , wherein the O-linked glycans comprise sialylated core structures.
8 . The purified pharmaceutical composition according to claim 1 , wherein each of the O-linked glycans comprises an O-glycan core structure selected from the group consisting of a mono-sialylated core 1 (Neu5Acα2-3Galβ1-3GalNAc), a neutral core 1 (Galβ1-3GalNAc), a mono-sialylated core 1 (Neu5Acα2-6(Galβ1-3)GalNAc), and a di-sialylated core 1 (Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAc).
9 . The purified pharmaceutical composition according to claim 8 , wherein the most abundant O-linked glycan core structure in the purified pharmaceutical composition is a mono-sialylated core 1 (Neu5Acα2-3Galβ1-3GalNAc).
10 . The purified pharmaceutical composition according to claim 1 , wherein at least 70% of the CTP-modified hGH polypeptides present in the purified pharmaceutical composition are highly glycosylated and comprise 13 to 18 O-linked glycans.
11 . The purified pharmaceutical composition according to claim 1 , wherein the most abundant form of the CTP-modified hGH polypeptides present in the purified pharmaceutical composition comprises 15 to 16 O-linked glycans.
12 . The purified pharmaceutical composition according to claim 1 , wherein at least 60% of the CTP-modified hGH polypeptides present in the purified pharmaceutical composition are sialylated.
13 . The purified pharmaceutical composition according to claim 12 , wherein the most abundant sialic acid in the purified pharmaceutical composition is Neu5Ac.
14 . The purified pharmaceutical composition according to claim 1 , wherein the CTP-modified hGH polypeptides present in the purified pharmaceutical composition that are highly glycosylated comprise an O-linked glycan core structure of a mono-sialylated core 1 (Neu5Acα2-3Galβ1-3GalNAc).
15 . The purified pharmaceutical composition according to claim 1 , comprising one or more of the following characteristics:
less than or equal 100 nanograms per milligram (ng/mg) of host cell proteins;
less than or equal to 10 picograms per milligram (pg/mg) DNA;
less than or equal to 50 ng/mL of methotrexate;
less than or equal 60 micrograms per milliliter (pg/ml) propylene glycol;
less than or equal 2.5 μg/mL Triton;
less than or equal 115 picograms per milliliter (pg/mL) insulin;
less than 250 μg/mL dimethyl sulfoxide (DMSO); or
less than or equal 10 colony forming units (cfu)/10 mL in a Bioburden assay.
16 . The purified pharmaceutical composition according to claim 1 , wherein the CTP-modified hGH polypeptides present in the pharmaceutical composition comprise two disulfide bridges.
17 . The purified pharmaceutical composition according to claim 16 , wherein the first of the two disulfide bridges is between cysteine residue 81 and cysteine residue 193 of SEQ ID NO: 7, and the second of the two disulfide bridges is between cysteine residue 210 and cysteine residue 217 of SEQ ID NO: 7.
18 . The purified pharmaceutical composition according to claim 1 , wherein the purified pharmaceutical composition is a maximally purified clarified harvest solution comprising the human CTP-modified hGH polypeptide.
19 . The purified pharmaceutical composition according to claim 1 , wherein at least 75% of the CTP-modified hGH polypeptides present in the purified pharmaceutical composition are highly glycosylated and comprise 13 to 18 O-linked glycans per molecule.
20 . The purified pharmaceutical composition according to claim 1 , wherein at least 80% of the CTP-modified hGH polypeptides present in the purified pharmaceutical composition are highly glycosylated and comprise-13 to 18 O-linked glycans per molecule.
21 . The purified pharmaceutical composition according to claim 1 , wherein the purified pharmaceutical composition further comprises 0.2% poloxamer 188.
22 . The purified pharmaceutical composition according to claim 1 , wherein the purified pharmaceutical composition is a sterile aqueous composition for subcutaneous (SC) injection.
23 . The purified pharmaceutical composition according to claim 1 , wherein the purified pharmaceutical composition further comprises 0.3% m-cresol.
24 . The purified pharmaceutical composition according to claim 1 , wherein step (c) comprises expanding clones obtained from a working cell bank (WCB) or master cell bank (MCB) that optimally expresses and secretes the CTP-modified hGH polypeptide.
25 . The purified pharmaceutical composition according to claim 1 , wherein at step (c) the clones express and secrete the CTP-modified hGH polypeptide at a level of at least 600 milligrams per liter (mg/L).
26 . The purified pharmaceutical composition according to claim 1 , wherein at step (c) the clones are expanded in solution through a series of sub-cultivating steps up to production bioreactor level.
27 . The purified pharmaceutical composition according to claim 26 , wherein the bioreactor comprises a disposable bioreactor or a stainless steel bioreactor, and wherein the bioreactor is run as a fed-batch bioreactor.
28 . The purified pharmaceutical composition according to claim 1 , wherein step (f) comprises sequentially performing a set of steps comprising:
i. concentrating and diafiltering the clarified harvest solution;
ii. obtaining the clarified harvest solution obtained following step i and inactivating viruses present in the clarified harvest solution by incubating in a solution toxic to the viruses;
iii. obtaining the clarified harvest solution from step ii and purifying the clarified harvest solution, wherein
the purifying is accomplished by sequentially passing the clarified harvest solution through an anion exchange column and a hydrophobic interaction column followed by a concentrating and diafiltering step, and
the purifying is followed by sequentially passing the clarified harvest solution through a Hydroxyapatite Mixed-Mode column and a cation exchange column;
iv. obtaining the clarified harvest solution following step iii and physically removing the clarified harvest solution from viruses by nanofiltration; and
v. obtaining the clarified harvest solution following step iv and concentrating and diafiltering the clarified harvest solution to arrive at a maximally purified clarified harvest solution containing the CTP-modified hGH polypeptide.
29 . The purified pharmaceutical composition according to claim 28 , wherein:
the anion exchange column is a DEAE-Sepharose column;
the hydrophobic column is a Phenyl Hydrophobic Interaction Chromatography (HIC) column;
the solution toxic to the viruses is a 1% Triton-X 100 solution;
the cation exchange column is a SP-Sepharose column; or
the viral clearance shows a viral log reduction factor (LRF) of about 22.
30 . The purified pharmaceutical composition according to claim 1 , wherein the method achieves at least a 20% recovery rate of the CTP-modified hGH polypeptide.
31 . The purified pharmaceutical composition according to claim 1 , wherein the method is an animal-derived free process.
Assignments (2)
SECURITY INTEREST
Recorded Jul 17, 2024
From: OPKO BIOLOGICS LTD.
To: HCR INJECTION SPV, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 068407/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 28, 2017
From: HERSHKOVITZ, OREN; MOSCHCOVICH, LAURA
To: OPKO BIOLOGICS LTD.
Reel/Frame 044047/0248 →
Continuity (4)
Provisional Application
62090104
· Dec 10, 2014
Provisional Application
62090116
· Dec 10, 2014
Provisional Application
62090124
· Dec 10, 2014
References Cited (400)
US 3791932A
· Schuurs et al.
· 1974
[cited by applicant]
US 3839153A
· Schuurs et al.
· 1974
[cited by applicant]
US 3850578A
· Macconnel
· 1974
[cited by applicant]
US 3850752A
· Schuurs et al.
· 1974
[cited by applicant]
US 3853987A
· Dreyer
· 1974
[cited by applicant]
US 3867517A
· Ling
· 1975
[cited by applicant]
US 3879262A
· Schuurs et al.
· 1975
[cited by applicant]
US 3901654A
· Gross
· 1975
[cited by applicant]
US 3935074A
· Rubenstein et al.
· 1976
[cited by applicant]
US 3984533A
· Uzgiris
· 1976
[cited by applicant]
US 3996345A
· Ullman et al.
· 1976
[cited by applicant]
US 4034074A
· Miles
· 1977
[cited by applicant]
US 4098876A
· Piasio et al.
· 1978
[cited by applicant]
US 4400316A
· Katsuragi et al.
· 1983
[cited by applicant]
US 4666828A
· Gusella
· 1987
[cited by applicant]
US 4683202A
· Mullis
· 1987
[cited by applicant]
US 4801531A
· Frossard
· 1989
[cited by applicant]
US 4853332A
· Mark et al.
· 1989
[cited by applicant]
US 4873316A
· Meade et al.
· 1989
[cited by applicant]
US 4879219A
· Wands et al.
· 1989
[cited by applicant]
US 4880634A
· Speiser
· 1989
[cited by applicant]
US 4911691A
· Aniuk et al.
· 1990
[cited by applicant]
US 5011771A
· Bellet et al.
· 1991
[cited by applicant]
US 5118666A
· Habener
· 1992
[cited by applicant]
US 5122458A
· Post et al.
· 1992
[cited by applicant]
US 5177193A
· Boime et al.
· 1993
[cited by applicant]
US 5192659A
· Simons
· 1993
[cited by applicant]
US 5272057A
· Smulson et al.
· 1993
[cited by applicant]
US 5281521A
· Trojanowski et al.
· 1994
[cited by applicant]
US 5338835A
· Boime
· 1994
[cited by applicant]
US 5405945A
· Boime et al.
· 1995
[cited by applicant]
US 5464764A
· Capecchi et al.
· 1995
[cited by applicant]
US 5487992A
· Capecchi et al.
· 1996
[cited by applicant]
US 5585345A
· Boime
· 1996
[cited by applicant]
US 5597797A
· Clark
· 1997
[cited by applicant]
US 5643575A
· Martinez et al.
· 1997
[cited by applicant]
US 5681567A
· Martinez et al.
· 1997
[cited by applicant]
US 5705478A
· Boime
· 1998
[cited by applicant]
US 5712122A
· Boime et al.
· 1998
[cited by applicant]
US 5759818A
· Boime
· 1998
[cited by applicant]
US 5792460A
· Boime
· 1998
[cited by applicant]
US 5824642A
· Attie et al.
· 1998
[cited by applicant]
US 5898030A
· Samaritani
· 1999
[cited by examiner]
US 5919455A
· Greenwald et al.
· 1999
[cited by applicant]
US 5929028A
· Skrabanja et al.
· 1999
[cited by applicant]
US 5932447A
· Siegall
· 1999
[cited by applicant]
US 5935924A
· Bunting et al.
· 1999
[cited by applicant]
US 5958737A
· Boime et al.
· 1999
[cited by applicant]
US 6028177A
· Boime
· 2000
[cited by applicant]
US 6083725A
· Selden et al.
· 2000
[cited by applicant]
US 6103501A
· Boime et al.
· 2000
[cited by applicant]
US 6113906A
· Greenwald et al.
· 2000
[cited by applicant]
US 6225449B1
· Boime
· 2001
[cited by applicant]
US 6238890B1
· Boime
· 2001
[cited by applicant]
US 6242580B1
· Boime et al.
· 2001
[cited by applicant]
US 6306654B1
· Boime et al.
· 2001
[cited by applicant]
US 6310183B1
· Johannessen et al.
· 2001
[cited by applicant]
US 6340742B1
· Burg et al.
· 2002
[cited by applicant]
US 6514729B1
· Bentzien
· 2003
[cited by applicant]
US 6897039B2
· Graversen et al.
· 2005
[cited by applicant]
US 7081446B2
· Lustbader
· 2006
[cited by applicant]
US 7091326B2
· Lee et al.
· 2006
[cited by applicant]
US 7094566B2
· Medlock et al.
· 2006
[cited by applicant]
US 7141547B2
· Rosen et al.
· 2006
[cited by applicant]
US 7202215B2
· Lustbader
· 2007
[cited by applicant]
US 7217689B1
· Elliot et al.
· 2007
[cited by applicant]
US 7371372B2
· Chaturvedi et al.
· 2008
[cited by applicant]
US 7371373B2
· Shirley et al.
· 2008
[cited by applicant]
US 7425539B2
· Donovan et al.
· 2008
[cited by applicant]
US 7442684B2
· Lustbader et al.
· 2008
[cited by applicant]
US 7459429B2
· Klima et al.
· 2008
[cited by applicant]
US 7459435B2
· Lehmann et al.
· 2008
[cited by applicant]
US 7459436B2
· Lehmann et al.
· 2008
[cited by applicant]
US 7553940B2
· Fares et al.
· 2009
[cited by applicant]
US 7553941B2
· Fares et al.
· 2009
[cited by applicant]
US 7563612B2
· Saxena et al.
· 2009
[cited by applicant]
US 7585837B2
· Shechter et al.
· 2009
[cited by applicant]
US 7649084B2
· Ferguson
· 2010
[cited by applicant]
US 7666835B2
· Bloom et al.
· 2010
[cited by applicant]
US 7795210B2
· Defrees et al.
· 2010
[cited by applicant]
US 8008454B2
· Lee et al.
· 2011
[cited by applicant]
US 8048846B2
· Chahal et al.
· 2011
[cited by applicant]
US 8048848B2
· Fares et al.
· 2011
[cited by applicant]
US 8048849B2
· Fares et al.
· 2011
[cited by applicant]
US 8063015B2
· Defrees et al.
· 2011
[cited by applicant]
US 8097435B2
· Fares et al.
· 2012
[cited by applicant]
US 8110376B2
· Fares et al.
· 2012
[cited by applicant]
US 8114836B2
· Fares et al.
· 2012
[cited by applicant]
US 8129330B2
· Martinez et al.
· 2012
[cited by applicant]
US 8304386B2
· Fares et al.
· 2012
[cited by applicant]
US 8426166B2
· Fares et al.
· 2013
[cited by applicant]
US 8450269B2
· Fares et al.
· 2013
[cited by applicant]
US 8465958B2
· Lopez De Leon et al.
· 2013
[cited by applicant]
US 8476234B2
· Fima et al.
· 2013
[cited by applicant]
US 8759292B2
· Fima et al.
· 2014
[cited by applicant]
US 8946155B2
· Fares et al.
· 2015
[cited by applicant]
US 9061072B2
· Hong et al.
· 2015
[cited by applicant]
US 9249407B2
· Fima et al.
· 2016
[cited by applicant]
US 9458444B2
· Fima et al.
· 2016
[cited by applicant]
US 9828417B2
· Fima et al.
· 2017
[cited by applicant]
US 9884901B2
· Fares et al.
· 2018
[cited by applicant]
US 20010007757A1
· Boime et al.
· 2001
[cited by applicant]
US 20010008895A1
· Silva Guisasola et al.
· 2001
[cited by applicant]
US 20020127652A1
· Schambye et al.
· 2002
[cited by applicant]
US 20040009902A1
· Boime et al.
· 2004
[cited by applicant]
US 20060088595A1
· Asakawa et al.
· 2006
[cited by applicant]
US 20060160177A1
· Okkels et al.
· 2006
[cited by applicant]
US 20070184530A1
· Fares et al.
· 2007
[cited by applicant]
US 20070298041A1
· Tomlinson
· 2007
[cited by applicant]
US 20080064856A1
· Warne et al.
· 2008
[cited by applicant]
US 20080206270A1
· Minev
· 2008
[cited by applicant]
US 20110004172A1
· Eckstein et al.
· 2011
[cited by applicant]
US 20110034374A1
· Bloom et al.
· 2011
[cited by applicant]
US 20110166063A1
· Bossard et al.
· 2011
[cited by applicant]
US 20140113860A1
· Fima et al.
· 2014
[cited by applicant]
US 20140170728A1
· Defrees et al.
· 2014
[cited by applicant]
US 20150038413A1
· Fares et al.
· 2015
[cited by applicant]
US 20150133636A1
· Xenopoulos et al.
· 2015
[cited by applicant]
US 20150158926A1
· Fares et al.
· 2015
[cited by applicant]
US 20160168588A1
· Hershkovitz et al.
· 2016
[cited by applicant]
CN 1528787A
· 2004
[cited by applicant]
CN 1528894A
· 2004
[cited by applicant]
CN 1847265
· 2006
[cited by applicant]
CN 102639144
· 2012
[cited by applicant]
CN 104010650
· 2014
[cited by applicant]
EP 0264166
· 1988
[cited by applicant]
EP 0374257A1
· 1990
[cited by applicant]
EP 0167825A2
· 1990
[cited by applicant]
EP 2420251A2
· 2012
[cited by applicant]
EP 2532674
· 2012
[cited by applicant]
EP 2420251
· 2013
[cited by applicant]
JP 2002226365A
· 2002
[cited by applicant]
JP 2002255857A
· 2002
[cited by applicant]
JP 2004269516A
· 2004
[cited by applicant]
JP 2015163650A
· 2015
[cited by applicant]
KR 20030037598A
· 2003
[cited by applicant]
KR 20050021502A
· 2005
[cited by applicant]
RU 2013106276
· 2014
[cited by applicant]
WO WO1989010756
· 1989
[cited by applicant]
WO WO1993006844
· 1993
[cited by applicant]
WO WO1994024148A1
· 1994
[cited by applicant]
WO WO1997015664
· 1997
[cited by applicant]
WO WO2000023472A2
· 2000
[cited by applicant]
WO WO2002036169A2
· 2002
[cited by applicant]
WO WO2002048194A1
· 2002
[cited by applicant]
WO WO2002085311A2
· 2002
[cited by applicant]
WO WO2003038100A1
· 2003
[cited by applicant]
WO WO2003046013A1
· 2003
[cited by applicant]
WO WO2003048210A1
· 2003
[cited by applicant]
WO WO2004006756
· 2004
[cited by applicant]
WO WO2004089280
· 2004
[cited by applicant]
WO WO2004111242
· 2004
[cited by applicant]
WO WO2005035761
· 2005
[cited by applicant]
WO WO2005080544
· 2005
[cited by applicant]
WO WO2006051288A2
· 2006
[cited by applicant]
WO WO2006134340
· 2006
[cited by applicant]
WO WO2007092252A2
· 2007
[cited by applicant]
WO WO2007094985
· 2007
[cited by applicant]
WO WO2007149406A2
· 2007
[cited by applicant]
WO WO2010007622
· 2010
[cited by applicant]
WO WO2010097077
· 2010
[cited by applicant]
WO WO2011004361
· 2011
[cited by applicant]
WO WO2011087672
· 2011
[cited by applicant]
WO WO2012008779
· 2012
[cited by applicant]
WO WO2012011752A2
· 2012
[cited by applicant]
WO WO2012011752
· 2012
[cited by applicant]
WO WO2012167251
· 2012
[cited by applicant]
WO WO2012173422
· 2012
[cited by applicant]
WO WO2013018098
· 2013
[cited by applicant]
WO WO2013096386
· 2013
[cited by applicant]
WO WO2013121416
· 2013
[cited by applicant]
WO WO2013157002
· 2013
[cited by applicant]
WO WO2013183052
· 2013
[cited by applicant]
WO WO2014080401
· 2014
[cited by applicant]
WO WO2016092550
· 2016
[cited by applicant]
WO WO2016203482
· 2016
[cited by applicant]
Garica-Campayo et al. Unmasking a new recognition signal for O-linked glycosylation in the chorionic gonadotropin beta subunit Molecular and Cellular Endocrinology 194:63-70; (2002) . (Year: 2002).
[cited by examiner]
Birken and Canfield Isolation and amino acid sequence of COOH-terminal fragments from the B subunit of Human choriogonadotropin. J. Biol. Chem. 252/15: 5386-5392; (1977). (Year: 1977).
[cited by examiner]
Alberts et al. “Molecular biology of the cell”, 5th ed. (Garland Science, 2008). 2002, p. 367.
[cited by applicant]
Ameredes et al. “Growth Hormone Improves Body Mass Recovery with Refeeding after Chronic Undernutrition-Induced Muscle Atrophy in Aging Male Rats” Journal of Nutrition. 129:2264-2270 (1999).
[cited by applicant]
Amirizahdeh et al. “Expression of biologically active recombinant B-domain-deleted human VIII in mammalian cells” Journal of Science, Islamic Republic of Iran. Abstract. 16(2):103-112, (2005).
[cited by applicant]
Anonymous “Prolor Biotech Announces Positive Results of its Obesity/Diabetes Drug Candidate in Preclinical Weight Loss Study”, Apr. 17, 2012, pp. 1-2; Retrieved from the Internet: URL;http://web.archive.org/web/20120526…
[cited by applicant]
Anonymous “Prolor Biotech Receives New U.S. Patent Allowance Covering Broad Applications of its CTP Platform for Long Acting Therapeutic Proteins”, Jul. 11, 2011, pp. 1-2; Retrieved from the Internet: URL;http://web.arc…
[cited by applicant]
Anonymous “Corporate Presentation—Lazard Capital Markets Healthcare Conference”, Nov. 15, 2011, pp. 1-19; Retrieved from the Internet: URL:http://web.archive.org/web/20110628023057/http://www.prolor-biotech.com/_Uploads…
[cited by applicant]
Anonymous “Corporate Presentation”, Jun. 1, 2011, pp. 1-35; Retrieved from the Internet: URL;http://web.archive.org/web/20110628023057/http://www.prolor-biotech.com/_Uploads/dbsAttachedFiles/prolorPresentationJune2011In…
[cited by applicant]
Anonymous “PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology”, Jan. 18, 2011, pp. 1-3; Retrieved from the Internet: URL;http://web.archive.org/web/20110123063420/http://www.news-med…
[cited by applicant]
Anson et al. “The gene structure of human anti-haemophilic factor IX”, The EMBO Journal (1984) 3(5):1053-1060.
[cited by applicant]
Askoy et al., “A study of the intracellular and secreted forms of the MUC2 mucin from the PC/AA intestinal cell line.” Glycobiology 9.7: 739-746 (1999).
[cited by applicant]
Banerji et al. “A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes” Cell 33:729-740 (1983).
[cited by applicant]
Barker et al. “An immunomagnetic-base method for the purification of ovarian cancer cells from patient-derived ascites”(Gynecologic Oncology 82, 57-63, 2001).
[cited by applicant]
Bengtsson et al. “Treatment of adults with growth hormone (GH) deficiency with recombinant human GH” J Clin Endocrinol Metab. Feb. 1993;76(2):309-17.
[cited by applicant]
Berntorp et al. “The pharmacokinetics of clotting factor therapy”; Haemophilia (2003) 9:353-359.
[cited by applicant]
Biller et al. “Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency”, J Clin Endocrinol Metab. Jun. 2011;96(6):1718-26.
[cited by applicant]
Bitter et al. “Expression and secretion vectors for yeast” (1987) Methods in Enzymol. 153:516-544.
[cited by applicant]
Bjorkman et al. Pharmacokinetics of Coagulation Factors Clinical Relevance for Patients with Haemophilia. Clin Pharmacokinet vol. 40 (11): 815-832 (2001).
[cited by applicant]
Bohl et al. “Improvement of erythropoiesis in b-thalassemic mice by continuous erythropoietin delivery from muscle” Blood 95:2793-2798 (2000).
[cited by applicant]
Boissel et al. “Erythropoietin structure-function relationships” The Journal of Biological Chemistry 268(21):15983-15993 (1993).
[cited by applicant]
Booth et al. “The use of a ‘universal’ yeast expression vector to produce an antigenic protein of
[cited by applicant]
Bouloux et al. “First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males.” Human Reproduction 16.8 (2001): 1592-1597.
[cited by applicant]
Brisson et al. “Expression of a bacterial gene in plants by using a viral vector” Nature, 310:511-514 (1984).
[cited by applicant]
Broglie et al. “Light-Regulated Expression of a Pea Ribulose-1,5-Bisphosphat Carboxylase Small Subunit Gene in Transformed Plant Cells” Science 224:838-843 (1984).
[cited by applicant]
Brunetti-Pierri et al. “Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B.” Human Gene Therapy 20.5: 479-485 (2009).
[cited by applicant]
Buchwald et al. “Long-term, continuous intravenous heparin administration by animplantable infusion pump in ambulatory patients with recurrent venous thrombosis” Surgery 88:507-516 (1980).
[cited by applicant]
Butler et al., “The beta-subunit of human chorionic gonadotrophin exists as a homodimer.” Journal of Molecular Endocrinology 22.2: 185-192 (1999).
[cited by applicant]
Byrne et al. “Multiplex gene regulation: A two-tiered approach to transgene regulation in transgenic mice” Proc. Natl. Acad. Sci USA 86:5473-5477 (1989).
[cited by applicant]
Calame et al. “Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci” Adv. Immunol 43:235-275 (1988).
[cited by applicant]
Carles-Bonnet et al. “H-Lys-Arg-Asn-Lys-Asn-Asn-OH is the minimal active structure of oxyntomodulin.” Peptides 17.3 (1996): 557-561.
[cited by applicant]
Cawley et al. “Developing long-acting growth hormone formulations”, Clinical Endocrinology (2013) 79, 305-309.
[cited by applicant]
Chan et al. “Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study”, Science vol. 279:563-566, Jan. 1998.
[cited by applicant]
Chen et al. “Recombinant carbohydrate variant of human choriogonadotropin beta-subunit (hCG beta) descarboxyl terminus (115-145). Expression and characterization of carboxyl-terminal deletion mutant of hCG beta in the b…
[cited by applicant]
Chen et al., “Glycoengineering Approach to Half-Life Extension of Recombinant Biotherapeutics.” Bioconjugate Chemistry 23.8: 1524-1533 (2012).
[cited by applicant]
Chen et al., “Modulating antibody pharmacokinetics using hydrophilic polymers.” Expert Opinion on Drug Delivery 8.9: 1221-1236 (2011).
[cited by applicant]
Chihara et al. “Clinical aspect of growth hormone deficiency in adults”, Nihon Naika Gakkai Zasshi. Sep. 10, 2000;89(9):2010-8; with English Abstract.
[cited by applicant]
Claxton et al., “A systematic review of the associations between dose regimens and medication compliance.” Clinical Therapeutics 23.8: 1296-1310 (2001).
[cited by applicant]
Cohen et al. “Oxyntomodulin suppresses appetite and reduces food intake in humans”, J Clin Endocrinol Metab. Oct. 2003;88(10):4696-701.
[cited by applicant]
Coleman et al., “Dosing frequency and medication adherence in chronic disease.” Journal of managed care pharmacy: JMCP 18.7: 527-539 (2012).
[cited by applicant]
Coruzzi et al. “Tissue-specific and light-regulated expression of a pea nuclear gene encoding the small subunit of ribulose-1,5-bisphosphate carboxylase” The EMBO Journal 3:1671-1680 (1984).
[cited by applicant]
Cutfield et al., “Non-compliance with growth hormone treatment in children is common and impairs linear growth.” PLoS One 6.1: e16223, p. 1-3 (2011).
[cited by applicant]
Dalton et al. “Over-expression of secreted proteins from mammalian cell lines”, Protein Sci. May 2014;23(5):517-25.
[cited by applicant]
Database Geneseq [Online] Apr. 7, 2005, “Human interferon beta (without signal peptide).” XP002664024 retrieved from EBI accession No. GSP: ADW02285, Database accession No. ADW02285.
[cited by applicant]
Database Geneseq [Online] 18 Mar. 24, 2005; “Epogen signal peptide”, XP002685292, retrieved from EBI accession No. GSP:ADS64918, Database accession No. ADW649.
[cited by applicant]
Davis CG et al. “Deletion of clustered O-linked carbohydrates does not impair function of low density lipoprotein receptor in transfected fibroblasts” J Biol Chem. 261(6):2828-38, Feb. 25, 1986.
[cited by applicant]
Diao et al. “The molecular design and drug development of recombinant long-acting follicle stimulating hormone” Acta pharmaceutica Sinica. Apr. 2012;47(4):421-6; Abstract.
[cited by applicant]
Diederichs et al., “Liposome in kosmetika und arzneimitteln.” Pharmazeutische Industrie 56.3: 267-275 (1994); German with Abstract/resume.
[cited by applicant]
Diness, et al. Lund-Hansen, and U. Hedner. “Effect of recombinant human FVIIA on warfarin-induced bleeding in rats.” Thrombosis research 59.6 (1990): 921-929.
[cited by applicant]
Dong et al. “The prolonged half-lives of new erythropoietin derivatives via peptide addition” Biochemical Research Communications, 339(1):380-385 (Jan. 6, 2006).
[cited by applicant]
Drake et al. “Optimizing GH therapy in adults and children” Endocr Rev. Aug. 2001;22(4):425-50. Review.
[cited by applicant]
Edlund et al. “Cell-Specific Expression of the Rat Insulin Gene: Evidence for Role of Two Distinct 5′ Flanking Elements” Science 230:912-916 (1985).
[cited by applicant]
Edmunds et al. “Plasma erythropoietin levels and acquired cystic disease of the kidney in patients receiving regular haemodialysis treatment” Br J Haematol. Jun. 1991;78(2):275-7.
[cited by applicant]
Eldem et al. “Optimization of spray-dried and congelated lipid micropellets and characterization of their surface morphology by scanning electron microscopy,” Pharmaceutical Research, vol. 8, issue 1 pp. 47-54, 1991.
[cited by applicant]
Eschbach et al. “Correction of the Anemia of End-Stage Rental Disease with Recombinant Human Erythropoietin”, The New England Journal of Medicine Jan. 8, 1987, vol. 316 No. 2, pp. 73-78.
[cited by applicant]
Fares “The role of O-linked and N-linked oligosaccharides on the structure-function of glycoprotein hormones: Development of agonists and antagonists”, Biochimica et Biophysica Acta (BBA)—General Subjects 1760.4: 560-56…
[cited by applicant]
Fares et al. “Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit” Proc Natl Acad Sci U S A., 89(10): 4304-4308, May 1…
[cited by applicant]
Fares et al. “Designing a long-acting human growth hormone (hGH) by fusing the carboxy-terminal peptide of human chorionic gonadotropin B-subunit to the coding sequence of hGH” Endocrinology 151(9):4410-4417 (2010).
[cited by applicant]
Fares et al. “Growth hormone (GH) retardation of muscle damage due toimmobilization in old rats. Possible intervention with a new long-acting recombinant GH” Ann N Y Acad Sci. 786:430-43 (Jun. 15, 1996).
[cited by applicant]
Fares et al. “Designing a Long Acting Erythropoietin by Fusing Three Carboxyl-Terminal Peptides of Human Chorionic Gondotropin [beta] Subunit to the N-Terminal and C-Terminal Coding Sequence”, International Journal of C…
[cited by applicant]
Fares et al., “Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin β-subunit to the coding sequence of human erythropoietin.” Endocrinology 148.10: 5081-50…
[cited by applicant]
Fayad et al. “Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas” Clin Lymphoma Myeloma. Dec. 2007;8 Suppl 2:S57-62.
[cited by applicant]
Fingl et al., “General Principles.” The Pharmacological Basis of Therapeutics (ed. Goodman, LS & Gilman, A,): 1-46 (1975).
[cited by applicant]
Fogarty, Patrick F. “Biological rationale for new drugs in the bleeding disorders pipeline.” ASH Education Program Book 2011.1 (2011): 397-404.
[cited by applicant]
Freshney “Culture of animal cells: A manual of basic technique” (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, pp. 1-4).
[cited by applicant]
Fuentes-Prior et al. “Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex” Nature. Mar. 30, 2000; 404 (6777):518-25.
[cited by applicant]
Furuhashi et al. “Fusing the carboxy-terminal peptide of the chorionic gonadotropin (CG)-subunit to the common alpha-submit:: Retention of O-linked glycosylation and enhanced in vivo bioactivity of chimeric human CG” Mo…
[cited by applicant]
Furuhashi et al. “Processing of O-linked glycosylation in the chimera consisting of alpha-subunit and carboxyl-terminal peptide of the human chorionic gonadotropin beta- subunit is affected by dimer formation with folli…
[cited by applicant]
Gao et al., “Erythropoietin gene therapy leads to autoimmune anemia in macaques” Blood 103(9):3300-3302 (2004).
[cited by applicant]
Garcia-Campayo et al. “Unmasking a new recognition signal for< i> O</i>-linked|glycosylation in the chorionic gonadotropin β subunit” Molecular and Cellular Endocrinology 194.1: 63-70 (2002).
[cited by applicant]
Gardella et al. “Expression of Human Parathyroid Hormone-( I-84) in
[cited by applicant]
Gellerfors et al. “Characterisation of a secreted form of recombinant derived human growth hormone, expressed in
[cited by applicant]
Genbank Accession No. NP 002045 (version 1), Sep. 6, 2014.
[cited by applicant]
Ghosh et al., “Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface.” Journal of Thrombosis and Haemostasis 5.2: 336-346 (2007).
[cited by applicant]
Gilboa et al., “Transfer And Expression of Cloned Genes Using Retroviral Vectors”, Biotechniques, vol. 4:504-512, (1986).
[cited by applicant]
Goodson, Ch. 6 ‘Dental Applications’ in “Medical applications of controlled release.” vol. 2: 115-138 (1984).
[cited by applicant]
Gossen et al. Inducible gene expression systems for higher eukaryotic cells. Current opinion in biotechnology. Oct. 1, 1994;5(5):516-20.
[cited by applicant]
Gurley et al. “Upstream Sequences Required for Efficient Expression of a Soybean Heat Shock Gene” Mol.Cell.Biol 6:559-565 (1986).
[cited by applicant]
Hacke et al. “Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)” JAMA. 1995;274(13):1017-1025.
[cited by applicant]
Hammerling et al. “In vitro bioassay for human erythropoietin based on proliferative stimulation of an erythroid cell line and analysis of carbohydrate-dependent microheterogeneity” Journal of Pharm. Biomed. Analysis 14…
[cited by applicant]
Havron et al. “OR2, 8 Phase I PK&PD profile of long acting bio-better CTP modified hGH (MOD-4023) in healthy volunteers”Growth Hormone & IGF Research. Jan. 1, 2010;20:S4-5.
[cited by applicant]
Heffernan et al., “Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism.” American Journal of Physiology-Endocrinology and Metabolism 279.3: E501-E507 (2000).
[cited by applicant]
Houdebine, L., “The methods to generate transgenic animals and to control transgene expression” Journal of Biotechnology 98:145-160 (2002).
[cited by applicant]
Huston et al. “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/IL2015/051196 dated Apr. 15, 2016.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/IL2015/051197 dated May 19, 2016.
[cited by applicant]
Isgaard et al. “Effects of local administration of GH and IGF-1 on longitudinal bone growth in rats” Am J Physiol. Apr. 1986;250(4 Pt 1):E367-72.
[cited by applicant]
Jarrousse et al. “Oxyntomodulin (glucagon-37) and its C-terminal octapeptide inhibit gastric acid secretion”, FEBS Lett. Aug. 19, 1985; 188(1): 81-4.
[cited by applicant]
Joshi et al. “Recombinant thyrotropin containing a beta-subunit chimera with the human chorionic gonadotropin-beta carboxy-terminus is biologically active, with a prolonged plasma half-life: role of carbohydrate in bioa…
[cited by applicant]
Kanda et al. “Genetic Fusion of an a-subunit Gene to the Follicle-Stimulating Hormone and Chorionic Gonadotropin-b Subunit Genes: Production of a Bifunctional Protein”, Molecular Endocrinolog, vol. 13, No. 11, p. 1873-1…
[cited by applicant]
Kelly et al. “Outcomes of patients with Burkitt lymphoma older than age 40 treated withintensive chemotherapeutic regimens.” Clin Lymphoma Myeloma. Aug. 2009;9(4):307-10.
[cited by applicant]
Kessler et al. “Structure and location of the O-glycosidic carbohydrate units of human chorionic gonadotropin” J Biol Chem. 25;254(16):7909-14 , Aug. 1979.
[cited by applicant]
Kessler et al., “Structures of N-Glycosidic Carbohydrate Units of Human Chorionic Gonadotropin” J Biol Chem. Aug. 25, 1979;254(16):7901-8.
[cited by applicant]
Kicman et al., “Human chorionic gonadotrophin and sport.” British Journal of Sports Medicine 25.2 : 73-80 (1991).
[cited by applicant]
Kieffer et al. “Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets” Endocrinology. Nov. 1996;137(11):5119-25.
[cited by applicant]
Knudsen et al. “Small-molecule agonists for the glucagon-like peptide 1 receptor”, PNAS, Jan. 16, 2007, vol. 104, No. 3, 937-942.
[cited by applicant]
Kontermann, “Half-Life Modulating Strategies—An Introduction.” Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives : 1-21 (2012).
[cited by applicant]
Kontermann, “Strategies for extended serum half-life of protein therapeutics.” Current opinion in Biotechnology 22.6: 868-876 (2011).
[cited by applicant]
Kotler et al., “Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients.” JAIDS Journal of Acquired Immune Deficiency Syndromes 35.3: 239-252 (2004).
[cited by applicant]
Krantz et al. “Specific binding of erythropoietin to spleen cells infected with the anemia strain of Friend virus” Proc Natl Acad Sci U S A. Dec. 1984;81(23):7574-8.
[cited by applicant]
Langer Robert “New Methods of Drug Delivery” Science 249:1527-1533 (1990).
[cited by applicant]
Larsen et al., “Accumulation of magnetic iron oxide nanoparticles coated with variably sized polyethylene glycol in murine tumors.” Nanoscale 4.7: 2352-2361 (2012).
[cited by applicant]
Le et al., “Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure.” Pediatr Infect Dis J vol. 32, pp. e155-e163 (2013).
[cited by applicant]
Lentz et al., “Posttranslational modification of the carboxy-terminal region of the. beta. subunit of human chorionic gonadotropin.” Biochemistry 23.22: 5330-5337 (1984).
[cited by applicant]
Li et al. “Bioassay of hGH .I. Weight gain of hypophysectomized rats”. Abstract, Yaowu Fenxi Zazhi 15(2), 3-7 (1995).
[cited by applicant]
Lippin et al. “Human erythropoietin gene therapy for patients with chronic renal failure” Blood 106(7):2280-2286 (2005).
[cited by applicant]
Littlewood, T.J. “Erythropoietin for the treatment of anemia associated with hematological malignancy” Hematol Oncol. Mar. 2001;19(1):19-30.
[cited by applicant]
Lo et al. “The effects of recombinant human growth hormone on body compositionandglucose metabolism in HIV-infected patients with fat accumulation” J Clin Endocrinol Metab. Aug. 2001;86(8):3480-7. PubMed PMID: 11502767.
[cited by applicant]
Lopez-Berenstein, Liposomes in the Therapy of Infectious Disease and Cancer, Lopez- Berestein and Fidler (eds.), Liss, New York, pp. 317-327 (1989).
[cited by applicant]
Lopez-Berestein et al. “Treatment of systemic fungal infections with liposomal amphotericin B.” Arch Intern Med. Nov. 1989;149(11):2533-6.
[cited by applicant]
Maheshwari et al., “Manipulation of Electrostatic and Saccharide Linker Interactions in the Design of Efficient Glycopolypeptide-Based Cholera Toxin Inhibitors.” Macromolecular bioscience 10.1: 68-81 (2010).
[cited by applicant]
Maston et al., “Chorionic gonadotropin beta subunit [
[cited by applicant]
Matsumoto et al. The measurement of low levels of factor VIII or factor IX inhemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. Journal of Thrombosis and Haemostasis vol. 4:377…
[cited by applicant]
Matsuo et al. “Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus” Nature. Jun. 18, 1981;291(5816):590-1.
[cited by applicant]
Maun et al., “Disulfide locked variants of factor VIIa with a restricted β-strandconformation have enhanced enzymatic activity.” Protein Science 14.5: 1171-1180 (2005).
[cited by applicant]
McAlister et al. “NMR analysis of the N-terminal SRCR domain of human CD5: engineering of a glycoprotein for superior characteristics in NMR experiments.” Protein Engineering 11.10: 847-853 (1998).
[cited by applicant]
Meulien et al., “Increased biological activity of a recombinant factor IX variant carrying alanine at position+ 1.” Protein Engineering 3.7: 629-633 (1990).
[cited by applicant]
Milton et al. The Delineation of a Decapeptide Gonadotropin-releasing Sequence in the Carboxyl-terminal Extension of the Human Gonadotropin releasing Hormone Precursor. The Journal of Biological Chemistry, vol. 261/36:1…
[cited by applicant]
Morgan et al. “The amino acid sequence of human chorionic gonadotropin. The alpha subunit and beta subunit”, J Biol Chem. Jul. 10, 1975;250(13):5247-58.
[cited by applicant]
Muleo et al. Small doses of recombinant factor Vila in acquired deficiencies of vitamin K dependent factors. Blood Coagulation & Fibrinolysis Abstract, 10(8), 521-522 (1999).
[cited by applicant]
Murray et al. “Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults”, Clinical Endocrinology (1999) 50, pp. 749-757.
[cited by applicant]
Musto “The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma” Leuk Lymphoma. Apr. 1998;29(3-4):283-91.
[cited by applicant]
Mutter et al. “A New Base-Labile Anchoring Group for Polymer-Supported Peptide Synthesis.” Helvetica chimica acta 67.7 (1984): 2009-2016.
[cited by applicant]
Mutter et al. “Evolution versus design: template-directed self-assembly of peptides toartificial proteins (TASP).” Chimia International Journal for Chemistry 54.10 (2000): 552-557.
[cited by applicant]
Nezu et al. “Treatment of idiopathic pituitary dwarfism with human growth hormone”, ournal of Nara Medical Association 1989, vol. 40, No. 1, p. 16-22; with English Abstract.
[cited by applicant]
Ngo et al. “Computational Complexity, Protein Structure Protein Prediction and the Levinthal Paradox” in Birkhauser The Protein Folding Problem And Tertiary Structure Prediction, pp. 433-440 and 492-495 (1994).
[cited by applicant]
Office Action for Japanese Application No. 2014-523441 dated May 24, 2016.
[cited by applicant]
Ogle et al. “Renal effects of growth hormone. I. Renal function and kidney growth”, Pediatr. Nephrol. vol. 6:394-398, 1992.
[cited by applicant]
Oosterhof et al. Regulation of whole body energy homeostasis with growth hormonereplacement therapy and endurance exercise Physiol Genomics. Jun. 28, 2011;43(12):739-48. doi: 10.1152/physiolgenomics.00034.2010. Epub Mar…
[cited by applicant]
Pedrosa et al., “Selective neoglycosylation increases the structural stability of vicilin, the 7S storage globulin from pea seeds.” Archives of Biochemistry and Biophysics 382.2: 203-210 (2000).
[cited by applicant]
Persson et al., “Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.” Proceedings of the National Academy of Sciences 98.24: 13583-13588 (2001).
[cited by applicant]
Persson et al. “Recombinant coagulation factor VIIa—from molecular to clinical aspects of a versatile haemostatic agent”, Thrombosis Research (2010) 125: 483-489.
[cited by applicant]
Philips A. “The challenge of gene therapy and DNA delivery” J Pharm. Pharmacology 53:1169-1174 (2001).
[cited by applicant]
Pierce et al. “Glycoprotein hormones: structure and function.” Annual review of biochemistry 50.1: 465-495 (1981).
[cited by applicant]
Pinkert et al. “An albumin enhancer located 10 kb upstream functions along with itspromoter to direct liver-specific expression in transgenic mice” Genes Dev. 1:268-277 (1987).
[cited by applicant]
Pocai et al. “Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice”, Diabetes, vol. 58, Oct. 2009, pp. 2258-2266.
[cited by applicant]
Polizzotti et al. “Effects of saccharide spacing and chain extension on toxin inhibition by glycopolypeptides of well-defined architecture”, Macromolecules 40.20: 7103-7110 (2007).
[cited by applicant]
Poreddy et al., “Exogenous fluorescent tracer agents based on pegylated pyrazinedyes for real-time point-of-care measurement of glomerular filtration rate.” Bioorganic & Medicinal Chemistry 20.8: 2490-2497 (2012).
[cited by applicant]
Puett et al. Structure-Function relationships of the luteinizing hormone receptor Ann. NY Acad. Sci. 1061: 41-54, 2005.
[cited by applicant]
Ramsey et al. “Surface treatments and cell attachment” In Vitro Cellular & Developmental Biology—Plant. Oct. 1, 1984;20(10):802-8.
[cited by applicant]
Rebois et al., “Hydrodynamic properties of the gonadotropin receptor from a murine Leydig tumor cell line are altered by desensitization.” Biochemistry 26.20: 6422-6428 (1987).
[cited by applicant]
Reichel “Sarcosyl-Page: a new electrophoretic method for the separation and immunological detection of PEGylated proteins.” Protein Electrophoresis. Humana Press 65-79 (2012).
[cited by applicant]
Reiter et al. “A multicenter study of the efficacy and safety of sustained release GH inthe treatment of naive pediatric patients with GH deficiency” J Clin Endocrinol Metab. 86(10):4700-6 (Oct. 2001).
[cited by applicant]
Ronzi et al. Optimisation of a freeze-drying process of high purity Factor VIII and Factor IX concentrates. Chemical Engineering and Processing. vol. 42:751-757 (2003).
[cited by applicant]
Rudman et al. “Effects of human growth hormone in men over 60 years old” N Engl J Med. Jul. 5, 1990;323(1):1-6.
[cited by applicant]
Runge et al. “Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity”, British Journal of Pharmacology (2003) 138, 787-794.
[cited by applicant]
Russell et al. “Local injections of human or rat growth hormone or of purified human somatomedin-C stimulate unilateral tibial epiphyseal growth in hypophysectomized rats” Endocrinology. Jun. 1985;116(6):2563-7.
[cited by applicant]
Sambrook, Joseph et al. “Molecular cloning: a laboratory manual.” Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 2 (2001), Index Only.
[cited by applicant]
Saudek et al. “A preliminary trial of the programmable implantable medication system for insulin delivery” N Engl J Med. 321:574 (1989).
[cited by applicant]
Schein, Catherine H. “The shape of the messenger: Using protein structure information to design novel cytokine-based therapeutics” Abstract; Current Pharmaceutical Design 8(24):2113-2129 (2002).
[cited by applicant]
Scheuttrumpf et al., “Factor IX variants improve gene therapy efficacy for hemophilia B.” Blood 105.6: 2316-2323 (2005).
[cited by applicant]
Schneider KH “GMP Requirements for master and working cell bank” Pharmazeutische Industrie. Jan. 1, 2005;67(11):1366-9.
[cited by applicant]
Schulte “Half-life extension through albumin fusion technologies”, Thrombosis Research (2009) 124 Suppl. 2;S6-S8.
[cited by applicant]
Sefton, “Implantable pumps.” Critical Reviews in Biomedical Engineering 14.3: 201-240 (1987).
[cited by applicant]
Shechter et al. “Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice”, FEBS Lett. Apr. 25, 2005;579(11):2439-44.
[cited by applicant]
Sheffield et al. “Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits”, Blackwell Publishing Ltd, British Journal of Haematology (2004) 126:565-573.
[cited by applicant]
Silverman et al. “A long-acting human growth hormone (Nutropin Depot): Efficacy and safety following two years of treatment in children with growth hormone deficiency” J Pediatr Endocrinol Metab. 15 Suppl 2:715-22. (May…
[cited by applicant]
Smeland et al. “Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens.” Ann Oncol. Jul. 2004;15(7):1072…
[cited by applicant]
Speiser et al. “Optimization of spray-dried and -congealed lipid micropellets and characterization of their surface morphology.” Pharm. Res. 8:47-54 (1991).
[cited by applicant]
Srour et al. “Regulation of human factor IX expression using doxycycline-inducible gene expression system.” Thromb Haemost 90.3 (2003): 398-405.
[cited by applicant]
Stuart et al. “Polycythemia vera” Am Fam Physician. May 1, 2004;69(9):2139-44.
[cited by applicant]
Studier F.W. et al “Use of T7 RNA Polymerase to Direct Expression of Cloned Genes” Methods in Enzymol. 185:60-89 (1990).
[cited by applicant]
Su et al. “Curcumin Inhibits Human Lung Cell Carcinoma Cancer Tumour Growth in a Murine Xenograft Model” (Phytother. Res. 24:189-191, 2010).
[cited by applicant]
Sugahara et al. “Characterization of the O-glycosylation sites in the chorionic gonadotropin β subunit in vivo using site-directed mutagenesis and gene transfer.” Journal of Biological Chemistry 271.34: 20797-20804 (199…
[cited by applicant]
Takamatsu et al. “Expression of bacterial chloramphenicol acetyltransferase gene in tobacco plants mediated by TMV-RNA” EMBO J 6:307-311 (1987).
[cited by applicant]
Takeya et al. “Bovine factor VII. Its purification and complete amino acid sequence”. Journal of Biological Chemistry. Oct. 15, 1988;263(29):14868-77.
[cited by applicant]
Tape et al. “Apolipoprotein A-I and apolipoprotein SAA half-lives during acute inflammation and amyloidogenesis”, Biochimica et Biophysica Acta (lipid and lipid metabolism) 1043: 295-300, 1990.
[cited by applicant]
Tharakan et al. “Emerging therapies in the treatment of ‘diabesity’: beyond GLP-1” Trends Pharmacol Sci. Jan. 2011;32(1):8-15.
[cited by applicant]
Treat, J, Greenspan, AR, and Rahman, A. Liposome Encapsulated Doxorubicin—Preliminary Results of Phase I and Phase II Trials. in: G Lopez-Berestein, IJ Fidler (Eds.) Liposomes in the Therapy of Infectious Diseases and C…
[cited by applicant]
Uenalp et al. “Factor VII deficiency associated with valproate treatment” Pediatrics International 50(3):403-405 (2008).
[cited by applicant]
Venn et al. “Biosynthesis and metabolism in vivo of intervertebral-disc proteoglycans in the mouse.” Biochem. J 215: 217-225 (1983).
[cited by applicant]
Verhoef et al. “Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment” Ann Hematol. Jan. 1992;64(1):16-21.
[cited by applicant]
Weiss et al. “Noncompliance in Neurologic Patients” Current Treatment Options in Neurology 7:419-425 (2005).
[cited by applicant]
Weissbach and Weissbach, “Methods for Plant Molecular Biology.” Selected Methods in Enzymology (USA) Section VIII: 421-463 (1988).
[cited by applicant]
Wells, J.A, “Additivity of Mutational Effects in Proteins” Biochemistry 29:8509-8517 (1990).
[cited by applicant]